Patent Assignment
Reel/Frame 030554/0301
Assignment of Assignor's Interest
Recorded: 2013-06-05
Pages: 33
Assignor
CYLENE PHARMACEUTICALS, INC.
Executed: 2013-04-29
Assignee
SENHWA BIOSCIENCES, INC.
9F, NO. 205-1, PEISHIN ROAD, SECTION 3, HSINTIEN DISTRICT, NEW TAIPEI CITY, TAIWAN
Covered Properties
(75)
Methods for Converting Quinolone Esters into Quinolone Amides
Quinolone Analogs
Methods of Preparing Quinolone Analogs
Fused Tricyclic Compounds as Serine-Threonine Protein Kinase and Parp Modulators
Therapeutic Kinase Modulators
Quinolone Analogs and Methods Related Thereto
Methods of Preparing Quinolone Analogs
Tetracyclic Imidazole Analogs
Application:
12/301,090 →
Publication:
US 2010/0063046
Pyridinone Analogs
Application:
12/303,952 →
Publication:
US 2011/0112086
Quinolone Analogs Derivatized with Sulfonic Acid, Sulfonate or Sulfonamide
Application:
12/303,957 →
Publication:
US 2010/0305136
Protein Kinase Modulators
Hydrazide Compounds and Uses Thereof
Application:
12/596,240 →
Publication:
US 2011/0065687
Treatment of Neoplastic Disorders Using Combination Therapies
Application:
12/684,053 →
Publication:
US 2010/0173013
Methods of Treating Disorders Associated with Protein Kinase CK2 Activity
Application:
12/762,038 →
Publication:
US 2010/0267753
Novel Protein Kinase Modulators
Application:
12/784,055 →
Publication:
US 2010/0298302
Pyrazolopyrimidines and Related Heterocycles as Kinase Inhibitors
Rhodanines and Related Heterocycles as Kinase Inhibitors
Application:
12/819,091 →
Publication:
US 2010/0331315
Novel Protein Kinase Modulators
Application:
12/869,335 →
Publication:
US 2011/0065698
Pharmaceutically Useful Heterocycle-Substituted Lactams
Application:
12/879,851 →
Publication:
US 2011/0071115
Novel Tricyclic Protein Kinase Modulators
Application:
12/883,688 →
Publication:
US 2011/0071136
Tricyclic Compounds and Pharmaceutical Uses Thereof
Application:
12/883,703 →
Publication:
US 2011/0065712
Biomarkers for predicting the sensitivity and response of protein kinase CK2-mediated diseases to CK2 Inhibitors
Application:
12/897,640 →
Publication:
US 2011/0212845
Pyrazolopyrimidines and Related Heterocycles as CK2 Inhibitors
Polymorphs and Salts of a Kinase Inhibitor
Fused Tricyclic Compounds as Serine-Threonine Protein Kinase and Parp Modulators
Quinolone Analogs and Methods Related Thereto
Deuterated Serine-Threonine Protein Kinase Modulators
Application:
13/242,525 →
Publication:
US 2012/0129849
Protein Kinase Modulators
Application:
13/315,103 →
Publication:
US 2012/0208792
Novel benzothiazole compounds and methods of use thereof
Application:
60/611,030 →
Aza-benzo[c]-fluoren-5-one analogs
Application:
60/638,603 →
Aza-benzo[c]-fluoren-5-one analogs
Application:
60/688,796 →
Novel benzothiazole compounds and methods of use thereof
Application:
60/688,986 →
Methods of preparing quinolone analogs
Application:
60/705,966 →
Tetracyclic imidazole analogs
Application:
60/801,550 →
Pyridinone analogs
Application:
60/811,990 →
Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
Application:
60/811,992 →
Casein kinase modulators
Application:
60/842,061 →
Casein kinase and parp modulators
Application:
60/844,542 →
Therapeutic combinations including PARP modulators
Application:
60/846,683 →
Casein kinase and PARP modulators
Application:
60/873,936 →
Casein Kinase and Parp Modulators
Application:
60/895,716 →
Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
Application:
60/904,694 →
Hydrazide Compounds and Uses Thereof
Application:
60/912,411 →
Therapeutic Kinase Modulators
Application:
60/969,556 →
Orally Bioavailable Ribosomal Rna Biosynthesis Inhibitors
Application:
60/978,042 →
Orally Bioavailable Ribosomal Rna Biosynthesis Inhibitors
Application:
61/038,681 →
Orally Bioavailable Ribosomal Rna Biosynthesis Inhibitors
Application:
61/045,933 →
Protein kinase modulators
Application:
61/067,845 →
Protein Kinase Modulators
Application:
61/103,908 →
Combination Therapies for Neoplastic Disorders
Application:
61/143,282 →
Methods of Treating Disorders Associated with Protein Kinase CK2 Activity
Application:
61/170,468 →
Pyrazolopyrimidines and Related Heterocycles as Kinase Inhibitors
Application:
61/180,090 →
Novel Protein Kinase Modulators
Application:
61/180,099 →
Rhodanines and Related Heterocycles as Kinase Inhibitors
Application:
61/218,314 →
Pyrazolopyrimidines and Related Heterocycles as Kinase Inhibitors
Application:
61/218,318 →
Novel Protein Kinase Modulators
Application:
61/218,347 →
Treatment of Neoplastic Disorders Using Combination Therapy
Application:
61/228,121 →
Novel Protein Kinase Modulators
Application:
61/237,227 →
Methods of Treating Disorders Associated with Protein Kinase CK2 Activity
Application:
61/240,165 →
Methods of Treating Disorders Associated with Protein Kinase CK2 Activity
Application:
61/242,227 →
Novel Tricyclic Protein Kinase Modulators
Application:
61/243,104 →
Tricyclic Compounds and Pharmaceutical Uses Thereof
Application:
61/243,107 →
Biomarkers for Sensitivity of Protein Kinase CK2-Mediated Diseases to CK2 Inhibitors
Application:
61/248,270 →
Biomarkers for Sensitivity of Protein Kinase CK2-Mediated Diseases to CK2 Inhibitors
Application:
61/255,805 →
Treatment of Neoplastic Disorders Using Combination Therapies
Application:
61/262,079 →
Polymorphs and Salts of a Kinase Inhibitor
Application:
61/263,638 →
Pyrazolopyrimidines and Related Heterocycles as Kinase Inhibitors
Application:
61/266,801 →
Novel Protein Kinase Modulators
Application:
61/287,646 →
Novel Protein Kinase Modulators
Application:
61/289,317 →
Methods of Treating Disorders Associated with Protein Kinase CK2 Activity
Application:
61/297,669 →
Biomarkers for Sensitivity of Protein Kinase CK2-Mediated Diseases to CK2 Inhibitors
Application:
61/323,771 →
Pyrazolopyrimidines and Related Heterocycles as CK2 Inhibitors
Application:
61/354,165 →
Biomarkers for sensitivity of protein kinase CK2-mediated diseases to CK2 inhibitors
Application:
61/380,685 →
Deuterated Serine-Threonine Protein Kinase Modulators
Application:
61/405,815 →
Pyrazolopyrimidines and Related Heterocycles as CK2 Inhibitors
Application:
61/494,660 →
Related Assignments
(21)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 28, 2005
From: WHITTEN, JEFFREY P.; PIERRE, FABRICE; REGAN, COLLIN; SCHWAEBE, MICHAEL
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 016846/0320 →
Assignment of Assignor's Interest
Dec 14, 2005
From: WHITTEN, JEFFREY P.; PIERRE, FABRICE; REGAN, COLLIN; SCHWAEBE, MICHAEL
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 017121/0746 →
Assignment of Assignor's Interest
Sep 22, 2006
From: CHUA, PETER C.; NAGASAWA, JOHNNY Y.; SCHWAEBE, MICHAEL; PIERRE, FABRICE
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 018301/0692 →
Assignment of Assignor's Interest
Sep 4, 2008
From: CHUA, PETER C.; PIERRE, FABRICE; WHITTEN, JEFFREY P.
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 021484/0011 →
Assignment of Assignor's Interest
Nov 4, 2008
From: PIERRE, FABRICE; HADDACH, MUSTAPHA
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 021784/0765 →
Assignment of Assignor's Interest
Nov 17, 2008
From: NAGASAWA, JOHNNY YASUO; PIERRE, FABRICE; HADDACH, MUSTAPHA; SCHWAEBE, MICHAEL
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 021846/0193 →
Assignment of Assignor's Interest
Dec 31, 2008
From: CHUA, PETER C.; NAGASAWA, JOHNNY Y.; SCHWAEBE, MICHAEL; PIERRE, FABRICE
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 022045/0732 →
Assignment of Assignor's Interest
Mar 5, 2009
From: WHITTEN, JEFFREY P.; SCHWAEBE, MICHAEL
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 022352/0743 →
Assignment of Assignor's Interest
May 19, 2009
From: CHUA, PETER C.; HADDACH, MUSTAPHA; NAGASAWA, JOHNNY YASUO; PIERRE, FABRICE
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 022706/0579 →
Assignment of Assignor's Interest
Jan 20, 2010
From: O'BRIEN, SEAN; DRYGIN, DENIS; PROFFITT, CHRISTOPHER B.; ANDERES, KENNA
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 023820/0633 →
Assignment of Assignor's Interest
Jun 24, 2010
From: HADDACH, MUSTAPHA; O'BRIEN, SEAN; ANDERES, KENNA
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 024591/0385 →
Assignment of Assignor's Interest
Jul 15, 2010
From: PIERRE, FABRICE; HADDACH, MUSTAPHA; CHUA, PETER C.
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 024689/0438 →
Assignment of Assignor's Interest
Sep 2, 2010
From: HADDACH, MUSTAPHA; RYCKMAN, DAVID M.
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 024931/0443 →
Assignment of Assignor's Interest
Sep 2, 2010
From: HADDACH, MUSTAPHA; TRAN, JOE
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 024931/0426 →
Assignment of Assignor's Interest
Sep 3, 2010
From: NAGASAWA, JOHNNY YASUO
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 024937/0194 →
Assignment of Assignor's Interest
Sep 3, 2010
From: PIERRE, FABRICE; SCHWAEBE, MICHAEL
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 024937/0180 →
Assignment of Assignor's Interest
Nov 29, 2010
From: HADDACH, MUSTAPHA; PIERRE, FABRICE
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 025427/0536 →
Assignment of Assignor's Interest
Dec 7, 2010
From: PIERRE, FABRICE; HADDACH, MUSTAPHA; REGAN, COLLIN F; RYCKMAN, DAVID M
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 025461/0815 →
Assignment of Assignor's Interest
Dec 9, 2010
From: HADDACH, MUSTAPHA; RYCKMAN, DAVID M.; RAFFAELE, NICHOLAS
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 025484/0608 →
Assignment of Assignor's Interest
Dec 9, 2010
From: HADDACH, MUSTAPHA; PIERRE, FABRICE
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 025484/0419 →
Assignment of Assignor's Interest
Dec 9, 2010
From: SCHWAEBE, MICHAEL; NAGASAWA, JOHNNY YASUO; HADDACH, MUSTAPHA
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 025484/0454 →